Harnessing Adap-ve NK Cells in Cancer Immunotherapy
Transcript of Harnessing Adap-ve NK Cells in Cancer Immunotherapy
![Page 1: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/1.jpg)
HarnessingAdap-veNKCellsinCancerImmunotherapy
Karl-JohanMalmberg,
MD.PhD.Prof.
![Page 2: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/2.jpg)
“Immunotherapyagainstcancerislikedryinganoceanwithanhairdryer”
![Page 3: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/3.jpg)
Challenge
To decipher the cellular and molecular mechanisms underlying immune failure and exploit this knowledge to convert clinical non-responders to responders
![Page 4: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/4.jpg)
![Page 5: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/5.jpg)
Regula-onofNKcellfunc-onbykillercellimmunoglobulin-likereceptors(KIR)
MalmbergandLjunggren,NatureReviewsImmunology2007
Virus infection / Tumor transformation
Normal cell
Cancer/ Infected cell
Transformation/Infection
![Page 6: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/6.jpg)
VariegatedKIRexpressionconfertoleranceandbroadspecifici-esinmissing-selfrecogni-on
Respondingcell
![Page 7: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/7.jpg)
Haploidentical NK cell therapy - Preliminary results from a Phase I/II trial at the Karolinska Institute
![Page 8: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/8.jpg)
NKcelltherapyacrossHLAbarriers–missingselfinthenewhost!
Kill
![Page 9: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/9.jpg)
ProtocolDesign–RefractoryAMLorMDS
Escala-ngdoseoftotallymphoidirradia-on
(TLI)andaddi-onofCyclosporineA
3
3
3 Infusion of over night
IL-2 activated Haploidentical NK cells
![Page 10: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/10.jpg)
6/16pa-entsreachingCRorPRbecomingeligibleforstemcell
transplanta-on
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
u ¤ è RAEB-2
u ¤ è MDS/AML
u ¤ ¢ è AML
u ¤ � ★ NK ✝
u � ★ ¢ è u CR/mCR/CRistart
u ¤ ✳ ✝ u mCR/PRstart
u � ★ NK ✝ u Stabledisease
u � ✝ � Responseend
✝ è Continuedresponse
✝
✝ ¤ SCT
u � ✝ ¢ DLI
✝ ★ Chemotherapy
u ✝ NK 2ndNK-treatment
✝ ✳ PTLDinCR
✝ ✝ Diseased
1year 2years 3years
![Page 11: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/11.jpg)
Non-responder Responder0
20
40
60
80
100
Freq
uenc
y liv
e lin
- CD
34+ 0.0480
Reduc-onofCD34+blastcounts
![Page 12: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/12.jpg)
Role for NK cells in the therapeutic effect?
![Page 13: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/13.jpg)
NKcellmicro-chimerismatday7-14correlateswithclinicalresponses
Per
cent
of p
atie
nts
(%)
p=0.03
Non-responder Responder
![Page 14: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/14.jpg)
Non-responder Responder0
10000
20000
30000
40000
GEO
M o
n liv
e lin
-C
D34
+CD
123+
CD
45R
A+ 0.0177
Immunoedi-ng–higherlevelsofHLAclassIonresidualblastsinresponders
Non-responder Responder0
200
400
600
800
Geo
M H
LA-E
on
live
lin-C
D34
+CD
123+
CD
45R
A+
0.0025
HLAclassI HLAE
![Page 15: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/15.jpg)
Harnessing the power of adaptive NK cells
![Page 16: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/16.jpg)
CyTOF:105
Horowitz et al., Science Transl. Med. 2013
NotallNKcellsareequal
![Page 17: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/17.jpg)
CMVSCT
CD8 NK
Beziat et al., Blood, 2013b
Beziat et al., Blood, 2013a
Björklund et al., , Blood, 2010
Andersson et al., Blood, 2009
Björkström et al., Blood, 2010
Björkström et al., Blood, 2012
CNV
![Page 18: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/18.jpg)
80
60
40
20
Blackrepertoires:CMV-nega-veindividualsn=48
Donor#164,C2C2CMV-posi-ve
Donor#59,C1C1CMV-posi-ve
PercentofN
Kcells
CMVisassociatedwithaclonal-likeexpansionofadap-veNKcells
BeziatV.etal.Blood2013
![Page 19: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/19.jpg)
Expandingtumor-reac-veNKcells
![Page 20: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/20.jpg)
CD2providessignal2inan-body-drivenadap-veNKcellresponses
Signal1Signal2
![Page 21: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/21.jpg)
Expansionplagorms
![Page 22: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/22.jpg)
Balancingnumbersandspecificity
![Page 23: Harnessing Adap-ve NK Cells in Cancer Immunotherapy](https://reader035.fdocuments.us/reader035/viewer/2022071612/6156f704a097e25c764f7843/html5/thumbnails/23.jpg)
Karolinska Institutet Per Ljungman Eva Hellström-Lindberg Petter Höglund Klas Kärre Sten Linnarsson Björn Önfelt Sören Lehman Björn Wahlin Hans-Gustaf Ljunggren Univ. of Minnesota Jeffrey Miller Sarah Cooley Univ. of Cambridge John Trowsdale James Traherne Stanford University Amir Horowitz Peter Parham
Oslo University Hospital (OUH) and UiO Johanna Olweus Arne Kolstad Eivind Hovig Andreas Brecht Harald Stenmark Kjetil Taskén Funding KI/SLL Theme Centers: Regenerative Medicine and IMTAC The Swedish Research Council The Swedish Cancer Foundation The Swedish Children's Cancer Foundation The Swedish Royal Society of Medicine Oslo University Hospital The Norwegian Cancer Society KG Jebsen Foundation
Malmberg group Karolinska Institutet Marie Schaffer Monika Enqvist Andreas Björklund Vivien Beziat (Paris) Lisa Liu Ebba Sohlberg Aline Pfefferle Oslo University Hospital Julie Hoel Merete Wiiger Vincent Yi Sheng Oei Eivind Ask-Hæggernes Jodie Peter Goodridge Kishan Chudasma Michelle Sætersmoen Trevor Clancy Benedikt Jakobs Axel Berg-Larsen
Acknowledgements